prikaz prve stranice dokumenta Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns
  Preuzmi
PDF 3.64 MB
Znanstveni rad - Izvorni znanstveni rad
Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns
Viruses, 15 (2023), 11; 2153. https://doi.org/10.3390/v15112153
Abassi, Leila; Bertoglio, Federico; Mačak Šafranko, Željka; Schirrmann, Thomas; Greweling-Pils, Marina; Seifert, Oliver; Khan, Fawad; Katzmarzyk, Maeva; Jacobsen, Henning; Gödecke, Natascha; Heine, Philip Alexander; Frenzel, André; Nowack, Helena; Dübel, Stefan; Kurolt, Ivan-Christian; Kontermann, Roland E.; Markotić, Alemka; Schubert, Maren; Hust, Michael; Čičin-Šain, Luka Više autora...

Citirajte ovaj rad

Abassi, L., Bertoglio, F., Mačak Šafranko, Ž., Schirrmann, T., Greweling Pils, M., Seifert, O. ... Čičin Šain, L. (2023). Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses, 15. (11). doi: 10.3390/v15112153

Abassi, Leila, et al. "Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns." Viruses, vol. 15, br. 11, 2023. https://doi.org/10.3390/v15112153

Abassi, Leila, Federico Bertoglio, Željka Mačak Šafranko, Thomas Schirrmann, Marina Greweling Pils, Oliver Seifert, Fawad Khan, et al. "Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns." Viruses 15, br. 11 (2023). https://doi.org/10.3390/v15112153

Abassi, L., et al. (2023) 'Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns', Viruses, 15(11). doi: 10.3390/v15112153

Abassi L, Bertoglio F, Mačak Šafranko Ž, Schirrmann T, Greweling Pils M, Seifert O, i sur.. Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. Viruses [Internet]. 25.10.2023. [pristupljeno 24.12.2024.];15(11). doi: 10.3390/v15112153

L. Abassi, et al., "Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns", Viruses, vol. 15, br. 11, Listopad 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:877574. [Citirano: 24.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:877574
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns
AutorLeila Abassi
AutorFederico Bertoglio
AutorŽeljka Mačak Šafranko
AutorThomas Schirrmann
AutorMarina Greweling-Pils
AutorOliver Seifert
AutorFawad Khan
AutorMaeva Katzmarzyk
AutorHenning Jacobsen
AutorNatascha Gödecke
AutorPhilip Alexander Heine
AutorAndré Frenzel
AutorHelena Nowack
AutorStefan Dübel
AutorIvan-Christian Kurolt
AutorRoland E. Kontermann
AutorAlemka Markotić
AutorMaren Schubert
AutorMichael Hust
AutorLuka Čičin-Šain
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za zarazne bolesti)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Imunologija
Sažetak (engleski)
As of now, the COVID-19 pandemic has spread to over 770 million confirmed cases and caused approximately 7 million deaths. While several vaccines and monoclonal antibodies (mAb) have been developed and deployed, natural selection against immune recognition of viral antigens by antibodies has fueled the evolution of new emerging variants and limited the immune protection by vaccines and mAb. To optimize the efficiency of mAb, it is imperative to understand how they neutralize the variants of concern (VoCs) and to investigate the mutations responsible for immune escape. In this study, we show the in vitro neutralizing effects of a previously described monoclonal antibody (STE90-C11) against the SARS-CoV-2 Delta variant (B.1.617.2) and its in vivo effects in therapeutic and prophylactic settings. We also show that the Omicron variant avoids recognition by this mAb. To define which mutations are responsible for the escape in the Omicron variant, we used a library of pseudovirus mutants carrying each of the mutations present in the Omicron VoC individually. We show that either 501Y or 417K point mutations were sufficient for the escape of Omicron recognition by STE90-C11. To test how escape mutations act against a combination of antibodies, we tested the same library against bispecific antibodies, recognizing two discrete regions of the spike antigen. While Omicron escaped the control by the bispecific antibodies, the same antibodies controlled all mutants with individual mutations.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaViruses
Brojčani podacivol. 15, br. 11, 2153
e-ISSN1999-4915
DOIhttps://doi.org/10.3390/v15112153
URN:NBNurn:nbn:hr:184:877574
Datum objave publikacije2023-10-25
URL dokumentahttps://www.mdpi.com/1999-4915/15/11/2153
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-10-26 10:36:55